FHI Clinical plans to acquire Triclinium Clinical Development to increase its access to the South African trials market.
The transaction – financial terms of which have not been disclosed – will strengthen FHI’s position in the African market and provide a Launchpad for further global expansion according to CEO Ted Fitzgerald.
“TCD’s experience and credibility in the South African market, marked by long-term client relationships and follow-on business, is a fit for our strategic vision.
“In addition to therapeutic alignment as an infectious disease CRO, TCD also provides the opportunity to expand our organizational ability to conduct trials in low- and middle-income countries better positioning us to repeat that success anywhere in the world.”
This was echoed by TCD CEO Abraham Van Wyk, who suggested that the firm’s offering would dovetail well.
“We knew FHI Clinical would be the best strategic fit for our organization as we have enjoyed a decade-long collaborative working relationship as preferred providers of the Global Health Clinical Consortium (GHCC).”
Market share
The merged company will have a workforce of 425 people operating in 12 countries worldwide.
FHI already has a 285 strong team in East and West Africa.
The firm said the acquisition was a sees a unique opportunity to further expand its share of the “market and become the dominant service provider in sub-Saharan Africa.”
Triclinium was established in 2000 with the aim of capturing a share of the local clinical trial market. The CRO runs studies in infectious diseases like malaria, HIV and tuberculosis.
According to the Centurion, Gauteng-headquartered CRO it is currently running trials of various vaccines and therapies across all phases of clinical research from single-dose Phase I trials to large Phase III and Phase IV trials.
Image: Stock Photo Secrets